WHO warns of immunisation strategy gaps amid measles outbreaks
The World Health Organisation (WHO) has reported a sharp drop in deaths from measles in recent decades yet warned that …
Post
-
-
Celltrion secures Health Canada go-ahead for Eylea biosimilar
South Korean biopharma Celltrion has obtained regulatory approval for its Eylea (aflibercept) biosimilar, Eydenzelt, from Health Canada. The therapy will now …
-
Podcast: What key trends are people talking about in pharma?
As the last leaves of Autumn fall, the healthcare conference scene ramps up its activity before the end of the …
-
Over half of European HIV patients diagnosed late, ECDC report finds
A European 2025 HIV/AIDS surveillance report has revealed that countries within the continent are currently failing to test and treat …
-
IASO Bio gains Hong Kong approval for Fucaso application
IASO Biotechnology has received the Hong Kong Department of Health's approval for its biologics licence application (BLA) for the fully …
-
MHRA approves Roche’s inavolisib for breast cancer
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Roche's Itovebi (inavolisib) to treat adults with …
-
Valneva trims R&D footprint by shutting French facility
Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by …
-
SK bolsters oncology pipeline in radiopharmaceutical licensing deal
SK Biopharmaceuticals has in-licensed its second radiopharmaceutical – this time from a US-based academic organisation – in a bid to …
-
BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 …
-
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
With a population of more than 670 million across hundreds of different ethnic groups living in the Association of Southeast …
-
Physicians see growing role of real-world evidence in clinical trials and beyond
The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around traditional …
-
Corstasis Therapeutics partners CVL for Enbumyst integration
Corstasis Therapeutics has announced a collaboration with Cardiovascular Logistics (CVL) to advance the adoption and integration of Enbumyst nasal spray …
-
The CGT frontier: what to prioritise in the transition from clinical to commercial
Projections show a $177.46 billion market by 2034 and an 18.7% CAGR. But here's the reality check: current manufacturing capacity …
-
Reeves’ Autumn Budget targets community health centres and NHS tech outlay
During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service (NHS) and, …
-
Dupixent gains chronic spontaneous urticaria indication in Europe
Regeneron and Sanofi’s Dupixent (dupilumab) has gained approval to treat chronic spontaneous urticaria (CSU) in Europe, adding yet another indication to …
